• 22Jul

    InnovaCare Health is primarily known for its Medicare advantage plans, physician practices, and great customer service. However, in InnovaCare’s most recent years, it has also been praised for its astounding leadership. CEO Rick Shinto’s and COO/COA Penelope Kokkinides’ involvement in InnovaCare, has greatly contributed to its rapid development and evolution.Rick Shinto has been engrossed in the health industry for a great amount of time. Before Shinto was part of InnovaCare, he was CEO at: Aveta Inc., MMM Healthcare, and PMC Medicare Choice. He has over 20 years of experience of managed healthcare experience. Shinto began his medical career an internist in California. He was awarded his bachelor’s degree at the University of California. Shinto then obtained his medical degree at the State University of New York.Shinto’s virtuous and exceptional work the medical field, has won him fine rewards. For his good morals, he was at one time rewarded a “Tribute for Caring” gala.

    This reward is only given to people who has made great healthcare service available for people with a low income. Shinto believes that having the ability to make health service more available and accessible is super gratifying. Penelope Kokkinides has also been highly involved in the field of health. Kokkinides previously worked as COO at Touchstone Health HMO and Aveta Inc. She started working in developing and implementing a healthcare model at Americare. Kokkinides was given her bachelor’s degree at Binghamton University.As CAO of InnovaCare, Penelope Kokkinides enjoys accepting new challenges and sharing her experiences.

    Kokkinides describes her work as diverse, with each day being dissimilar. She enjoys traveling during work and communicating with business partners through video chat. Kokkinides praises the most recent advancements in technology, since it makes her work much more enjoyable and relaxed.InnovaCare Health regards its patients and customers as the company’s highest priority. Also, InnovaCare is able to regulate and maintain both service and quality all across the U.S. and Canada. The healthcare company works each and everyday to insure it is can sustain value for every single plan. InnovaCare strives to insure that it is available to be used by as many people as possible.

  • 03May

    A healthcare growth equity firm, known as Foresite Capital, announced that Molly He, PhD., has joined as a project partner. Previously, she was working at Illumina as a senior director for over 15 years. Foresite Company will be getting a professional who has experience in genomic research and pharmaceutical. The announcement was made by Foresite Managing director and Principal executive officer, Jim Tananbaum. According to Tananbaum, Dr. He is among the scientific researchers who are well respected and Foresite is lucky to have such an addition to the team as it continues to expand.

    Dr. He studied at Nankain University and was awarded a Bachelor’s Degree in Biochemist and from the University of California, Los Angeles she got Ph.D. in protein biophysics. She has written and published over 20 documents and has more than 20 patent applications. She has also issued patents in the field personalizing medication and sequencing of next-generation. Doing this as well as the experience she had at Illumina working as a developer of protein reagent, makes her ideal for the Foresite Capital position. Together with the company, Dr. He will help in the development of next generation sequencing portfolio.

    Jim Tananbaum graduate from Yale University with a B.S and B.S.E.E., from Harvard Medicine School with an M.D. from MIT with and M.S and Harvard Business School with an M.B.A. is the founder and the CEO of the Foresite Capital. He is known as an industry leader and has over 25 years of experience in the healthcare field. Not only does he practice it, but, he also invests in it. Some of the investments that he made were Tarse Therapeutics in 2012, Sequenta in 2013, and Allergen Research Corporation in 2015. He was also a partner at Sierra Ventures; here he worked to establish practices that will be used by the healthcare services investments. The returns that he got from his investment was what he used as Foresite capital.

    Before starting the Foresite Capital, Tananbaum founded GelTex Pharmaceuticals. However, he sold the company for $1.6 billion. He also co-founded Theravance Biopharma, Inc. He founded Foresite Capital in 2011 with $1.1 Billion assets that were under management. The reason for setting up the firm was to collaborate with entrepreneurs with vision and focus on building value and improving patient care dramatically. More details can be found on his Crunchbase profile.

    Follow him on Twitter

    Click here: https://www.forbes.com/profile/jim-tananbaum/



Single Links